Maryam Barkhordar
Publication Activity (10 Years)
Years Active: 2022-2024
Publications (10 Years): 8
Publications (10 Years): 8
Publications
- Mohammad Reza Taherian, Pouya Azarbar, Maryam Barkhordar, Shahin Toufani, Leyla Sharifi Aliabadi, Tanaz Bahri, Mohammad Ahmadvand, Marjan Yaghmaie, Alireza Daneshvar, Mohammad Vaezi
- Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, Mohammad VaeziEvaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines 11 (1) (2023)
- Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, Mohammad VaeziEvaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines 11 (1) (2023)
- Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, Mohammad VaeziEvaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines 11 (1) (2023)
- Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, Mohammad VaeziEvaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines 11 (1) (2023)
- Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, Mohammad VaeziEvaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines 11 (1) (2023)
- Maryam Barkhordar, Fatemeh Tajic Rostami, Marjan Yaghmaie, Mehrdad Abbaszadeh, Bahram Chahardouli, Seyed Asadollah Mousavi